Compare Gogoro Inc (GGR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs IDEXX Laboratories, Inc. — how do they compare? Gogoro Inc trades at $3.02 (market cap $56.21M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 719.3× Gogoro Inc's market cap, and Gogoro Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GGR | IDXX | |
|---|---|---|
Market Cap | $56.21M | $40.43B |
Volume | 14,026 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $766.68 |
52-Week Low | $2.20 | $504.70 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | $342.65M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
